{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+of+IR+tablet", "query": { "intervention": "Placebo of IR tablet" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 64, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+of+IR+tablet&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-15T20:36:29.631Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05239468", "title": "Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Bezafibrate 100 mg", "type": "DRUG" }, { "name": "Bezafibrate 200 mg", "type": "DRUG" }, { "name": "Obeticholic Acid 5 mg", "type": "DRUG" }, { "name": "Obeticholic Acid placebo", "type": "DRUG" }, { "name": "Bezafibrate Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-03-21", "completion_date": "2025-09-01", "has_results": true, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239468" }, { "nct_id": "NCT00226395", "title": "Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Pain" ], "interventions": [ { "name": "Oxymorphone immediate release", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2004-09", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2024-01-02", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00226395" }, { "nct_id": "NCT06042855", "title": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Susanna Naggie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 3214, "start_date": "2023-09-05", "completion_date": "2024-11-04", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 110, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06042855" }, { "nct_id": "NCT03187795", "title": "Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Spinal Cord Injuries", "Urinary Bladder, Neurogenic" ], "interventions": [ { "name": "Oxybutynin Chloride IR", "type": "DRUG" }, { "name": "Mirabegron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kessler Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 62, "start_date": "2019-04-03", "completion_date": "2022-03-30", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 1, "location_summary": "West Orange, New Jersey", "locations": [ { "city": "West Orange", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03187795" }, { "nct_id": "NCT03515044", "title": "Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overt Hepatic Encephalopathy" ], "interventions": [ { "name": "40 mg Rifaximin SSD once daily", "type": "DRUG" }, { "name": "40 mg Rifaximin SSD twice daily", "type": "DRUG" }, { "name": "80 mg Rifaximin SSD once daily", "type": "DRUG" }, { "name": "80 mg Rifaximin SSD twice daily", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 71, "start_date": "2018-09-13", "completion_date": "2020-03-12", "has_results": true, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 34, "location_summary": "Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more", "locations": [ { "city": "Corona del Mar", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bristol", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515044" }, { "nct_id": "NCT03547583", "title": "Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 789, "start_date": "2018-06-15", "completion_date": "2019-11-04", "has_results": true, "last_update_posted_date": "2021-01-06", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 29, "location_summary": "Beverly Hills, California • Carmichael, California • West Hills, California + 26 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Carmichael", "state": "California" }, { "city": "West Hills", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Trumbull", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547583" }, { "nct_id": "NCT00357994", "title": "Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Parkinson's Disease" ], "interventions": [ { "name": "Levodopa carbidopa intestinal gel (LCIG)", "type": "DRUG" }, { "name": "Placebo gel", "type": "DRUG" }, { "name": "Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets", "type": "DRUG" }, { "name": "Placebo (PBO) oral capsules", "type": "DRUG" }, { "name": "CADD-Legacy® 1400 ambulatory infusion pump", "type": "DEVICE" }, { "name": "PEG tube", "type": "DEVICE" }, { "name": "J-tube", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 36, "start_date": "2009-01", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2015-01-16", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 8, "location_summary": "Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00357994" }, { "nct_id": "NCT05081245", "title": "ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism Spectrum Disorder" ], "interventions": [ { "name": "ML-004 (IR)/(ER) tablet", "type": "DRUG" }, { "name": "ML-004 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MapLight Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "12 Years to 45 Years" }, "enrollment_count": 168, "start_date": "2022-09-13", "completion_date": "2026-04-17", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 24, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Glendale, California + 21 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Rafael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05081245" }, { "nct_id": "NCT04575610", "title": "IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "PF-06650833", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2020-11-27", "completion_date": "2021-10-06", "has_results": false, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04575610" }, { "nct_id": "NCT02526524", "title": "Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Met DR", "type": "DRUG" }, { "name": "Met IR", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elcelyx Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 571, "start_date": "2015-09", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2018-04-27", "last_synced_at": "2026-09-15T20:36:29.631Z", "location_count": 134, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 107 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02526524" } ] }